Maintenance risankizumab sustains induction response in patients with Crohn’s disease in a randomized Phase 3 trial
J Crohns Colitis 2024;18:416–423 doi: 10.1093/ecco-jcc/jjad168
Subcutaneous risankizumab maintenance therapy results in durable improvement in clinical and endoscopic outcomes over one year in patients with moderately to severely active Crohn’s disease. Endpoint achievement tended to be achieved in a higher proportion of patients treated with 360mg risankizumab than 160mg risankizumab, and both doses were higher when compared to placebo.